These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2564831)

  • 21. Differences between agonist and antagonist binding to alpha 1-adrenergic receptors of intact and broken-cell preparations.
    Sladeczek F; Bockaert J; Mauger JP
    Mol Pharmacol; 1983 Nov; 24(3):392-7. PubMed ID: 6138703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle.
    Muramatsu I; Ohmura T; Kigoshi S; Hashimoto S; Oshita M
    Br J Pharmacol; 1990 Jan; 99(1):197-201. PubMed ID: 1970493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-adrenergic receptors in human blood vessels.
    van Brummelen P; Jie K; van Zwieten PA
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):33S-39S. PubMed ID: 2871855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased affinity and preference of halogenated derivatives of BE 2254 for alpha 1-adrenoceptors demonstrated by functional and binding experiments.
    Schlicker E; Brodde OE; Göthert M; Schaperdoth M
    J Cardiovasc Pharmacol; 1984; 6(6):1238-44. PubMed ID: 6084785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of maturation on alpha-adrenergic receptor affinity and occupancy in small cerebral arteries.
    Elliott SR; Pearce WJ
    Am J Physiol; 1994 Aug; 267(2 Pt 2):H757-63. PubMed ID: 7915085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonlinear relationship between alpha 1-adrenergic receptor occupancy and norepinephrine-stimulated calcium flux in cultured vascular smooth muscle cells.
    Colucci WS; Brock TA; Gimbrone MA; Alexander RW
    Mol Pharmacol; 1985 May; 27(5):517-24. PubMed ID: 2985950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of alpha 1- and alpha 2-adrenergic receptors.
    Bylund DB; U'Prichard DC
    Int Rev Neurobiol; 1983; 24():343-431. PubMed ID: 6317599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines.
    Daly RN; Sulpizio AC; Levitt B; DeMarinis RM; Regan JW; Ruffolo RR; Hieble JP
    J Pharmacol Exp Ther; 1988 Oct; 247(1):122-8. PubMed ID: 2902209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occupancy of alpha 1-adrenergic receptors and contraction of rat vas deferens.
    Minneman KP; Fox AW; Abel PW
    Mol Pharmacol; 1983 Mar; 23(2):359-68. PubMed ID: 6300645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Changes of alpha 1-adrenoceptor and its subtypes in blood vessels of old rats].
    Han QD; Li JL
    Sheng Li Xue Bao; 1991 Feb; 43(1):22-30. PubMed ID: 1645477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [3H]Dihydroergocryptine binding to alpha adrenergic receptors in canine aortic membranes.
    Tsai BS; Lefkowitz RJ
    J Pharmacol Exp Ther; 1978 Mar; 204(3):606-14. PubMed ID: 24730
    [No Abstract]   [Full Text] [Related]  

  • 32. The pharmacology of fluparoxan: a selective alpha 2-adrenoceptor antagonist.
    Halliday CA; Jones BJ; Skingle M; Walsh DM; Wise H; Tyers MB
    Br J Pharmacol; 1991 Apr; 102(4):887-95. PubMed ID: 1677298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature.
    Murata S; Taniguchi T; Takahashi M; Okada K; Akiyama K; Muramatsu I
    J Urol; 2000 Aug; 164(2):578-83. PubMed ID: 10893647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role.
    Suzuki E; Tsujimoto G; Tamura K; Hashimoto K
    Mol Pharmacol; 1990 Nov; 38(5):725-36. PubMed ID: 1978244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective suppression by bunazosin of alpha-adrenergic agonist evoked elevation of intraocular pressure in sympathectomized rabbit eyes.
    Nishimura K; Kuwayama Y; Matsugi T; Sun N; Shirasawa E
    Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1761-6. PubMed ID: 8097189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional evidence for functional subclassification of alpha-2 adrenoceptors based on a new selective antagonist, SK&F 104856.
    Hieble JP; Sulpizio AC; Edwards R; Chapman H; Young P; Roberts SP; Blackburn TP; Wood MD; Shah DH; Demarinis RM
    J Pharmacol Exp Ther; 1991 Nov; 259(2):643-52. PubMed ID: 1682482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional variations in alpha adrenergic receptor interactions of [3H]-dihydroergokryptine in calf brain: implications for a two-site model of alpha receptor function.
    Peroutka SJ; Greenberg DA; U'Prichard DC; Snyder SH
    Mol Pharmacol; 1978 May; 14(3):403-12. PubMed ID: 26861
    [No Abstract]   [Full Text] [Related]  

  • 38. Tight agonist binding may prevent the correct interpretation of agonist competition binding curves for alpha 2-adrenergic receptors.
    Convents A; De Backer JP; Convents D; Vauquelin G
    Mol Pharmacol; 1987 Jul; 32(1):65-72. PubMed ID: 2885739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
    Kenny BA; Miller AM; Williamson IJ; O'Connell J; Chalmers DH; Naylor AM
    Br J Pharmacol; 1996 Jun; 118(4):871-8. PubMed ID: 8799556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors.
    U'Prichard DC; Greenberg DA; Snyder SH
    Mol Pharmacol; 1977 May; 13(3):454-73. PubMed ID: 17827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.